These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 16027705)

  • 1. Radiological evidence of early cerebral microvascular disease in young children with Fabry disease.
    Cabrera-Salazar MA; O'Rourke E; Charria-Ortiz G; Barranger JA
    J Pediatr; 2005 Jul; 147(1):102-5. PubMed ID: 16027705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ; Banikazemi M
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amelioration of white-matter lesions in a patient with Fabry disease.
    Yamadera M; Yokoe M; Beck G; Mihara M; Oe H; Yamamoto Y; Sakoda S
    J Neurol Sci; 2009 Apr; 279(1-2):118-20. PubMed ID: 19185318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance image findings in 5 young patients with Fabry disease.
    Politei JM; Capizzano AA
    Neurologist; 2006 Mar; 12(2):103-5. PubMed ID: 16534447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cerebral vasculopathy of Fabry disease.
    Moore DF; Kaneski CR; Askari H; Schiffmann R
    J Neurol Sci; 2007 Jun; 257(1-2):258-63. PubMed ID: 17362993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
    Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
    Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurology of Fabry disease.
    Low M; Nicholls K; Tubridy N; Hand P; Velakoulis D; Kiers L; Mitchell P; Becker G
    Intern Med J; 2007 Jul; 37(7):436-47. PubMed ID: 17547722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
    Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
    Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. White matter lesion severity in male and female patients with Fabry disease.
    Fellgiebel A; Müller MJ; Mazanek M; Baron K; Beck M; Stoeter P
    Neurology; 2005 Aug; 65(4):600-2. PubMed ID: 16116124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Stroke in Fabry disease. More than a simple stenosis].
    Politei JM
    Medicina (B Aires); 2006; 66(5):467-71. PubMed ID: 17137181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac manifestations of Anderson-Fabry disease in children and adolescents.
    Kampmann C; Wiethoff CM; Whybra C; Baehner FA; Mengel E; Beck M
    Acta Paediatr; 2008 Apr; 97(4):463-9. PubMed ID: 18363956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microvascular angina as prehypertrophic presentation of Fabry disease cardiomyopathy.
    Frustaci A; Russo MA; Francone M; Chimenti C
    Circulation; 2014 Oct; 130(17):1530-1. PubMed ID: 25332282
    [No Abstract]   [Full Text] [Related]  

  • 15. Ultrastructural study of renal involvement in two females with Anderson-Fabry disease.
    Tosoni A; Nebuloni M; Zerbi P; Vago L; Comotti C; Sessa A
    Ultrastruct Pathol; 2005; 29(3-4):203-7. PubMed ID: 16036875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabry disease: cardiac manifestations and therapeutic options.
    Pierre-Louis B; Kumar A; Frishman WH
    Cardiol Rev; 2009; 17(1):31-5. PubMed ID: 19092368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabry disease with aortic regurgitation.
    Choi S; Seo H; Park M; Kim J; Hwang S; Kwon K; Her K; Won Y
    Ann Thorac Surg; 2009 Feb; 87(2):625-8. PubMed ID: 19161799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of Fabry disease with central nervous system (CNS) demyelinating lesions: a double trouble?
    Invernizzi P; Bonometti MA; Turri E; Benedetti MD; Salviati A
    Mult Scler; 2008 Aug; 14(7):1003-6. PubMed ID: 18632784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy.
    Vedder AC; Cox-Brinkman J; Hollak CE; Linthorst GE; Groener JE; Helmond MT; Scheij S; Aerts JM
    Mol Genet Metab; 2006 Nov; 89(3):239-44. PubMed ID: 16765076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fabry disease and the skin: data from FOS, the Fabry outcome survey.
    Orteu CH; Jansen T; Lidove O; Jaussaud R; Hughes DA; Pintos-Morell G; Ramaswami U; Parini R; Sunder-Plassman G; Beck M; Mehta AB;
    Br J Dermatol; 2007 Aug; 157(2):331-7. PubMed ID: 17573884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.